journal article·2018-10Open access

Cyclodextrin Modulated Type I Collagen Self‐Assembly to Engineer Biomimetic Cornea Implants

Shoumyo Majumdar, Xiaokun Wang, Sven D. Sommerfeld, Jemin Jeremy Chae, Evangelia‐Nefeli Athanasopoulou, Lucas S. Shores, Xiaodong Duan, L. Mario Amzel, Francesco Stellacci, Oliver Schein, Qiongyu Guo, Anirudha Singh, Jennifer H. Elisseeff

Advanced Functional Materials· Volume 28· Issue 41

Abstract

Abstract Collagen‐rich tissues in the cornea exhibit unique and highly organized extracellular matrix ultrastructures, which contribute to its high load‐bearing capacity and light transmittance. Corneal collagen fibrils are controlled during development by small leucine‐rich proteoglycans (SLRPs) that regulate the fibril diameter and spacing in order to achieve the unique optical transparency. Cyclodextrins (CDs) of varying size and chemical functionality for their ability to regulate collagen assembly during vitrification process are screened in order to create biosynthetic materials that mimic the native cornea structure. Addition of βCD to collagen vitrigels produces materials with aligned fibers and lamellae similar to native cornea, resulting in mechanically robust and transparent materials. Biochemistry analysis revealed that CD interacts with hydrophobic amino acids in collagen to influence assembly and fibril organization. To translate the self‐assembled collagen materials for cornea reconstruction, custom molds for gelation and vitrification are engineered to create βCD/Col implants with curvature matching that of the cornea. Acellular βCD/Col materials are implanted in a rabbit partial keratoplasty model with interrupted sutures. The implants demonstrate tissue integration and support re‐epithelialization. Therefore, the addition of CD molecules regulates collagen self‐assembly and provides a simple process to engineer corneal mimetic substitutes with advanced structural and functional properties.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Proteoglycans and glycosaminoglycans research · Corneal Surgery and Treatments · Connective tissue disorders research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Translational Tissue Engineering Center Johns Hopkins University Baltimore MD 21231 USA

Department of Materials Science and Engineering Johns Hopkins University Baltimore MD 21218 USA

Department of Biomedical Engineering Johns Hopkins University Baltimore MD 21218 USA

Wilmer Eye Institute Johns Hopkins School of Medicine Baltimore MD 21231 USA

Supramolecular Nanomaterials and Interfaces Laboratory École Polytechnique Fédérale de Lausanne Lausanne 1015 Switzerland

Eyegenix LLC Honolulu HI 96817 USA

Department of Biophysics and Biophysical Chemistry Johns Hopkins University Baltimore MD 21205 USA

Department of Biomedical Engineering Southern University of Science and Technology Shenzhen Guangdong 518055 China

Deparment of Urology Johns Hopkins School of Medicine & Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore MD 21218 USA

Funding

Research to Prevent Blindness · National Eye Institute · U.S. Army Materiel Command

References (46)

Show source-provided references
1. 10.1074/jbc.M11070920010.1074/jbc.M110709200 ↗
2. 10.1016/j.biomaterials.2010.01.10110.1016/j.biomaterials.2010.01.101 ↗
3. 10.1146/annurev-bioeng-071811-15002110.1146/annurev-bioeng-071811-150021 ↗
4. 10.1089/ten.tea.2012.058410.1089/ten.tea.2012.0584 ↗
5. Freund D. E. · Invest. Ophthalmol. Visual Sci. · 1995 · 36 · 1508
6. 10.1136/bjo.85.4.37910.1136/bjo.85.4.379 ↗
7. Komai Y. · Invest. Ophthalmol. Visual Sci. · 1991 · 32 · 2244
8. 10.1073/pnas.11115059810.1073/pnas.111150598 ↗
9. 10.1016/S1350-9462(00)00016-110.1016/S1350-9462(00)00016-1 ↗
10. 10.1074/jbc.M80659020010.1074/jbc.M806590200 ↗
11. 10.1016/j.exer.2014.08.00110.1016/j.exer.2014.08.001 ↗
12. 10.1016/j.jsb.2013.05.02210.1016/j.jsb.2013.05.022 ↗
13. Qazi Y. · J. Clin. Cell. Immunol. · 2013
14. 10.1097/ACI.0b013e32833dfa1110.1097/ACI.0b013e32833dfa11 ↗
15. Fink N. · Cesk. Oftalmol. · 1994 · 50 · 3
16. 10.1016/S0161-6420(94)31138-910.1016/S0161-6420(94)31138-9 ↗
17. 10.1038/eye.2011.12210.1038/eye.2011.122 ↗
18. 10.1016/j.actbio.2013.04.01410.1016/j.actbio.2013.04.014 ↗
19. 10.1016/j.biomaterials.2012.03.03310.1016/j.biomaterials.2012.03.033 ↗
20. 10.1039/C5NR03826J10.1039/C5NR03826J ↗
21. 10.1126/scitranslmed.300102210.1126/scitranslmed.3001022 ↗
22. 10.1016/j.biomaterials.2013.11.07910.1016/j.biomaterials.2013.11.079 ↗
23. 10.1016/j.actbio.2015.04.01810.1016/j.actbio.2015.04.018 ↗
24. 10.1039/c3sm52097h10.1039/c3sm52097h ↗
25. 10.1016/j.biomaterials.2012.06.04110.1016/j.biomaterials.2012.06.041 ↗
26. 10.1038/nchem.112310.1038/nchem.1123 ↗
27. 10.1016/j.actbio.2014.06.00610.1016/j.actbio.2014.06.006 ↗
28. Chellam J. · Int. J. Pharma Bio Sci. · 2013 · 4 · 795
29. 10.3727/00000000478398388210.3727/000000004783983882 ↗
30. 10.1002/jbm.b.3135110.1002/jbm.b.31351 ↗
31. 10.2174/15748881079044280410.2174/157488810790442804 ↗
32. 10.1016/j.biomaterials.2012.07.06210.1016/j.biomaterials.2012.07.062 ↗
33. 10.1002/jbm.b.3338110.1002/jbm.b.33381 ↗
34. 10.1042/bst011013610.1042/bst0110136 ↗
35. 10.1016/j.biomaterials.2013.08.06110.1016/j.biomaterials.2013.08.061 ↗
36. 10.1111/aos.1250310.1111/aos.12503 ↗
37. 10.1021/jo010046q10.1021/jo010046q ↗
38. 10.1039/C7CP04009A10.1039/C7CP04009A ↗
39. 10.1038/nprot.2006.20210.1038/nprot.2006.202 ↗
40. 10.1021/jp205303710.1021/jp2053037 ↗
41. 10.1093/protein/gzg13710.1093/protein/gzg137 ↗
42. 10.1016/j.saa.2007.10.05410.1016/j.saa.2007.10.054 ↗
43. 10.1016/j.bpj.2010.01.03010.1016/j.bpj.2010.01.030 ↗
44. 10.1016/j.ijpharm.2009.11.03510.1016/j.ijpharm.2009.11.035 ↗
45. 10.1016/j.micron.2007.06.01710.1016/j.micron.2007.06.017 ↗
46. 10.1002/jor.110009061710.1002/jor.1100090617 ↗